Clinical trials: Tardive Dyskinesia, open to volunteers
Tardive Dyskinesia
Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia
The primary objective of this study is to evaluate the efficacy of NBI-1065890 compared with placebo for the treatment of tardive dyskinesia (TD) in adult participants.
- Trial name
- NCT07365462
- Testing
- NBI-1065890
- Where
- 18 sites in United States
- Volunteers
- 100 people
- Sponsor
- Neurocrine Biosciences
Schizophrenia, Schizoaffective Disorder
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder
- Trial name
- NCT07105111
- Testing
- Valbenazine
- Where
- 19 sites in United States
- Volunteers
- 100 people
- Sponsor
- Neurocrine Biosciences
Tardive Dyskinesia (TD)
Safety and Efficacy of LPM3770164 Sustained-release Tablets in Patients With Tardive Dyskinesia
This is a multicenter, randomized, double-blind, placebo-controlled parallel-group trial to evaluate the safety, tolerability, preliminary efficacy and PK characteristics of multiple doses of LPM3770164 sustained-release tablets…
- Trial name
- NCT06731868
- Testing
- LPM3770164 sustained release tablet 5 mg, LPM3770164 sustained release tablet 10 mg, LPM3770164 sustained release tablet 20 mg
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Luye Pharma Group Ltd.
Tardive Dyskinesia, Repetitive Transcranial Magnetic Stimulation
Single-Center, Double-Blind, Randomized, Placebo-Controlled Study on Efficacy and Safety of rTMS (With Precise Localization) in Relieving Motor Symptoms of TD
# Brief Summary (English Version) Tardive Dyskinesia (TD) is a hyperkinetic movement disorder induced by long-term use of dopamine receptor blockers and related drugs.
- Trial name
- NCT07173920
- Testing
- repetitive Transcranial Magnetic Stimulation
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Peking University Sixth Hospital
Extrapyramidal Symptoms, Drug-induced Parkinsonism
A Computer-Assisted Tool for Objective Assessment of Extrapyramidal Symptoms
This prospective, single-center observational study aims to develop and validate a computer-assisted tool for the objective quantitative assessment of extrapyramidal symptoms (EPS).
- Conditions
- Extrapyramidal Symptoms, Drug-induced Parkinsonism, Akathisia, Drug-Induced, Tardive Dyskinesia (TD)
- Trial name
- NCT07715994
- Testing
- Computer-Assisted Objective Assessment of Extrapyramidal Symptoms
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Shanghai Mental Health Center
Schizophrenia, Schizoaffective Disorder
Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
To test the feasibility of studying effects of smoking cessation with varenicline on antipsychotic drug-induced neurological side effects, we propose a 12 week pilot study of smoking cessation treatment with varenicline in 10…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Tobacco Smoking, Tardive Dyskinesia
- Trial name
- NCT03495024
- Testing
- Varenicline
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Corporal Michael J. Crescenz VA Medical Center
Tardive Dyskinesia
Studying Patterns in Patient Engagement Among Tardive Dyskinesia Patients
The statistical analysis of the collected data aims to reveal the many factors that influence patient involvement in clinical trials.
- Trial name
- NCT06218719
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Tardive Dyskinesia, Intellectual Disability
Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities
The primary goal of this study is to investigate the efficacy of deutetrabenazine treatment of TD in this previously untreated patient population.
- Conditions
- Tardive Dyskinesia, Intellectual Disability, Developmental Disabilities
- Trial name
- TD-AIDD (NCT06997198)
- Testing
- Deutetrabenazine Oral Capsule
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University Hospitals Cleveland Medical Center